<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>Inbox Robot: Cordis News</title>
<link>http://www.inboxrobot.com/news/cordis</link><description>Constantly updated news and information about a variety of topics.</description><item>
<title>Clinical Data Indicate that Percutaneous Coronary Intervention with the Cypher Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery</title>
<link>http://www.inboxrobot.com/news.php?fid=186687077</link>
<pubDate>5 Sep 2008 17:04 GMT</pubDate>
<description>
...  London Chest Hospital, Barts and London National Health Service Trust, London, UK, and one of  ...  providing limited support for the CARDia trial, Cordis Corporation has no financial relationship with Dr.  ...  or PCI. The trial, conducted at 24 medical centers throughout the United Kingdom and Ireland,  ...
</description>
</item><item>
<title>CYPHER SELECT Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks</title>
<link>http://www.inboxrobot.com/news.php?fid=186562075</link>
<pubDate>4 Sep 2008 20:30 GMT</pubDate>
<description>
... CYPHER SELECT Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of  ...  for Treatment of Heart Attacks ) -- Cordis Corporation announced that it has received CE  ...
</description>
</item><item>
<title>Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease</title>
<link>http://www.inboxrobot.com/news.php?fid=186553523</link>
<pubDate>4 Sep 2008 19:17 GMT</pubDate>
<description>
...  London Chest Hospital, Barts and London National Health Service Trust, London, UK, and one of  ...  providing limited support for the CARDia trial, Cordis Corporation has no financial relationship with Dr.  ...  or PCI. The trial, conducted at 24 medical centers throughout the United Kingdom and Ireland,  ...
</description>
</item><item>
<title>Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease Results C</title>
<link>http://www.inboxrobot.com/news.php?fid=186546858</link>
<pubDate>4 Sep 2008 18:29 GMT</pubDate>
<description>
...  London Chest Hospital, Barts and London National Health Service Trust, London, UK, and one of  ...  providing limited support for the CARDia trial, Cordis Corporation has no financial relationship with Dr.  ...  and were The trial, conducted at 24 medical centers throughout the United Kingdom and Ireland,  ...
</description>
</item><item>
<title>Research and Markets: ev3 Inc. Product Pipeline Analysis Report Features Key Employee Biographies</title>
<link>http://www.inboxrobot.com/news.php?fid=186538001</link>
<pubDate>4 Sep 2008 17:31 GMT</pubDate>
<description>
...  Bard, Inc. - Cook Group Incorporated - Cordis Corporation - Medtronic, Inc. - Micrus Endovascular  ...  Inc. - Micrus Endovascular Corporation - Possis Medical, Inc. - Terumo Corporation - The Spectranetics  ...
</description>
</item><item>
<title>Research and Markets: Bioscan Technologies Inc. Product Pipeline Analysis Report Provides Details on Clinical Trials for Products in Development</title>
<link>http://www.inboxrobot.com/news.php?fid=186517650</link>
<pubDate>4 Sep 2008 15:33 GMT</pubDate>
<description>
...  Disclaimer The following companies are the major competitors of Bioscan Technologies Inc.: - AGA Medical Corporation - Belmont Instrument Corporation - Cordis Corporation - OVALUM Ltd. - USCI Japan, Ltd. For more information visit ...
</description>
</item><item>
<title>First patient enrolled in study evaluating S.M.A.R.T. Nitinol self-expandable stent</title>
<link>http://www.inboxrobot.com/news.php?fid=186508403</link>
<pubDate>4 Sep 2008 14:30 GMT</pubDate>
<description>
...  and efficacy of the S.M.A.R.T. Nitinol Self-Expandable Stent System in treating patients with obstructive superficial  ...  Drug Administration that, if approved, will allow Cordis to market the S.M.A.R.T. Stent for this  ...  extremities and an important area of unmet medical need,&quot; says Campbell Rogers, M.D., Chief Technology  ...
</description>
</item><item>
<title>First Patient Enrolled In Study Evaluating S.M.A.R.T.(R) Nitinol Self-Expandable Stent System In Leg Disease</title>
<link>http://www.inboxrobot.com/news.php?fid=186483416</link>
<pubDate>4 Sep 2008 12:53 GMT</pubDate>
<description>
... Cordis Corporation announced the first patient enrollment in  ...  efficacy of the S.M.A.R.T.  Nitinol Self-Expandable Stent System in treating patients with obstructive superficial  ...  extremities and an important area of unmet medical need,&quot; says Campbell Rogers, M.D., Chief Technology  ...
</description>
</item><item>
<title>Hydromer, Inc. and Medinol Ltd. Enter Into a Coating Services and Supply Agreement for Stent Placeme</title>
<link>http://www.inboxrobot.com/news.php?fid=186315993</link>
<pubDate>3 Sep 2008 15:28 GMT</pubDate>
<description>
...  and Supply Agreement with edinol Ltd., a Medical Device Company that develops and manufactures innovative  ...  hydrogel products for medical device, pharmaceutical, animal health, cosmetic, personal care, and industrial uses. For  ...  Today Medinol&apos;s coronary stents are distributed by Cordis (a Johnson &amp; Johnson company). Pebax   ...
</description>
</item><item>
<title>--&gt; Hydromer, Inc. and Medinol Ltd. Enter Into a Coating Services and Supply Agreement for Stent Placement Catheters</title>
<link>http://www.inboxrobot.com/news.php?fid=186313617</link>
<pubDate>3 Sep 2008 15:06 GMT</pubDate>
<description>
...  and Supply Agreement with Medinol Ltd., a Medical Device Company that develops and manufactures innovative  ...  hydrogel products for medical device, pharmaceutical, animal health, cosmetic, personal care, and industrial uses. For  ...  Today Medinol&apos;s coronary stents are distributed by Cordis (a Johnson &amp; Johnson company). Pebax   ...
</description>
</item><item>
<title>Hydromer, Inc. and Medinol Ltd. Enter Into a Coating Services and Supply Agreement for Stent Placement Catheters</title>
<link>http://www.inboxrobot.com/news.php?fid=186310606</link>
<pubDate>3 Sep 2008 14:55 GMT</pubDate>
<description>
...  and Supply Agreement with edinol Ltd., a Medical Device Company that develops and manufactures innovative  ...  hydrogel products for medical device, pharmaceutical, animal health, cosmetic, personal care, and industrial uses. For  ...  Today Medinol&apos;s coronary stents are distributed by Cordis (a Johnson &amp; Johnson company). Pebax   ...
</description>
</item><item>
<title>First Patient Enrolled in Study Evaluating S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in Leg Disease</title>
<link>http://www.inboxrobot.com/news.php?fid=186158863</link>
<pubDate>2 Sep 2008 19:32 GMT</pubDate>
<description>
... Cordis Corporation today announced the first patient enrollment  ...  efficacy of the S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in treating patients with obstructive superficial  ...  extremities and an important area of unmet medical need,&quot; says Campbell Rogers, M.D., Chief Technology  ...
</description>
</item><item>
<title>Sports-Related Sudden Cardiac Death Is Reduced By Pre-Participation Cardiovascular Screening</title>
<link>http://www.inboxrobot.com/news.php?fid=185995197</link>
<pubDate>1 Sep 2008 19:30 GMT</pubDate>
<description>
...  transient myocardial lesion, such as myocarditis, commotio cordis , acute electrolytic depletion, when the cause  ...  by the general population to be the healthiest members of society. The possibility that highly  ...
</description>
</item></channel>
</rss>
